Regulatory and Testing Requirements of the Bacterial Endotoxin Testing (BET) or LAL Program

Recorded Webinar | Carl Patterson | From: Sep 15, 2021 - To: Dec 31, 2021

Training Options & Pricing

Error Conference Exists In Wish-list.

Congrats Conference Added In Wish-list.

Recording
⊖   ⊕$229  
DVD
⊖   ⊕$249  
Recording + DVD
⊖   ⊕$389  
Transcript (Pdf)
⊖   ⊕$229  
Recording & Transcript (Pdf)
⊖   ⊕$379  
DVD & Transcript (Pdf)
⊖   ⊕$389  


Order Form

Bacterial Endotoxin Test (BET) is a vital safety requirement in the current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and the medical device quality system regulations. A solid grasp of the concept of this critical release assay, its application, and its importance to the manufacture of cGMP products is paramount. This helps avoid costly errors, batch disposal, expensive failure investigations, and delays in the release of products that some manufacturers have undergone. This webinar has been designed to provide the experienced technician with an extensive understanding of how a Limulus amebocyte lysate (LAL) testing program can be applied to quality control so that regulatory requirements enforced by the EU and the FDA are met.

Areas Covered in the Session:-

  • Introduction to current USP <85> Bacterial Endotoxin Test
  • Types of Bacterial Endotoxin Test Methodologies
  • Advantages and Disadvantages of Each Methodology and Choosing the Appropriate Method
  • Initiating a Bacterial Endotoxin Test-Initial Considerations
  • LAL Testing Materials and Reagent Qualification
  • Products Receipt, Handling, and Storage
  • Product Processing
  • Handling, Investigating and Resolving Failure and Out of Specification (OOS) Results
  • Relationship of Endotoxin Test (LAL) with other Production and Process Controls

Why You Should Attend:-

The current requirements of USP <85> Bacterial Endotoxin Test (BET) and European Pharmacopoeia (Chapter 2.6.14) will be discussed in this 60-minute webinar. It will address the different LAL testing methodologies and how to choose the best test method applicable to the product type. This webinar will outline the significance, regulatory, and testing requirements of products for compliance by applying the sequential steps in testing the product to rule out the presence of Endotoxins. Companies in the Pharmaceutical, Biotechnology, and Medical Device Industries that manufacture cGMP products requiring bacterial Endotoxin release assay will greatly benefit from this program.

Who Should Attend:-

  • Quality Assurance Departments
  • Research and Development Departments
  • Regulatory Affairs Departments
  • Quality Control Departments
  • Manufacturing Departments
  • Engineering Departments
  • Compliance Departments
  • Quality Auditors
  • Microbiology Specialists

Carl Patterson

Carl Patterson is a seasoned Pharmaceutical Manufacturing, Aseptic Processing, and Quality Assurance professional who is based in San Diego, California. As soon as he discovered the importance of biotechnology in the area, he was inspired to enter the pharmaceutical manufacturing industry. However, his avid interest in biology, microbiology, and biochemistry officially began when he served in the U.S. Army as a Preventative Medicine Specialist and a Licensed Vocational Nurse.

To date, Carl has now garnered over two decades’ worth of extensive hands-on expertise. Currently, he is the Chief Consultant of his very own consultant business called aseptic-process.net, where he specializes in the aseptic processing of pharmaceutical products in the pharmaceutical manufacturing sector.

Furthermore, Carl holds various degrees and certifications, including an M.S. in Biomedical Quality Systems from San Diego State University, a B.S. in Microbiology from the University of Texas, and Specialized Certificates in QA/QC & Biotechnology from UCSD.